HEALTHCARE, STOCKS
Jay Silverman
Editor,
Medical Technology Stock Letter
- Editor of Medical Technology Stock Letter
- Ranked #1 in Biotechnology of the WSJ's Best on the Street 2000
- Frequent Contributor to Print and Television Media
Follow
About Jay
Jay Silverman has been a biotechnology and pharmaceuticals analyst for over 25 years and has a tremendous track record in analyzing and recommending biotech stocks. He is an editor of Medical Technology Stock Letter. In 2000, he was ranked #1 in Biotechnology by The Wall Street Journal's Best on the Street annual analyst survey, in addition to being a "Home-Run Hitter" for stock selection. As an analyst, he was frequently quoted in The Wall Street Journal, TIME, Fortune and featured on CNBC and CNN. Mr. Silverman graduated from the University of Pennsylvania's Wharton School in 1987 with a B.S. in Economics/Finance.
Jay's Articles
Esperion (ESPR) is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid (BA) — branded NEXLETOL — already FDA approved to reduce LDL cholesterol, explains Jay Silverman, an analyst with The Medical Technology Stock Letter.
Jay Silverman
HEALTHCARE
Tickers: ESPR
Precigen (PGEN) is a novel biotech company with a broad R&D pipeline focused on immuno-oncolgoy, autoimmune and infectious diseases, explains Jay Silverman, an analyst with The Medical Technology Stock Letter.
Jay Silverman
HEALTHCARE
Tickers: PGEN
With the launch of its leading GNRH blocking pill — Orgovyx (relugolix) — heading to a best-in-class prostate cancer drug, Myovant (MYOV) is a top pick for 2022, asserts Jay Silverman, biotechnology expert and editor of The Medical Technology Stock Letter.
Jay Silverman
HEALTHCARE
Tickers: MYOV
In our 2021 Top Picks report, Jay Silverman — a leading biotech sector analyst and contributing editor to The Medical Technology Stock Letter — chose Celldex Therapeutics (CLDX), which rose 100% last year. He again selects the stock as a Top Pick for 2022.
Jay Silverman
HEALTHCARE
Tickers: CLDX
Newsletter Contributions
Medical Technology Stock Letter
The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.
Learn More